Sjögren’s syndrome doesn’t have universally recognized clinical stages the way cancer does, but researchers have identified a four-phase model that maps how the disease typically develops: an initiation stage, a preclinical stage, an asymptomatic stage, and an overt stage. Most people searching for “stages” want to understand how this condition progresses over time, what to expect at each point, and what signals that things are getting worse. Here’s what the current evidence shows.
The Four-Phase Disease Model
The most widely referenced framework divides Sjögren’s into four stages based on what’s happening in the body, not just what you can feel. In the initiation stage, a combination of genetic susceptibility and environmental triggers (like a viral infection) sets off an immune response against the moisture-producing glands. Nothing is noticeable yet. During the preclinical stage, the immune system begins producing antibodies, particularly anti-SSA (Ro) antibodies, that can show up on blood tests years before any symptoms appear. Some people stay in this phase for a long time without ever knowing something is wrong.
The asymptomatic stage is where things get tricky. Immune cells have begun infiltrating the salivary and tear glands, causing measurable damage, but the glands still produce enough moisture that you don’t notice dryness. A biopsy at this point might already show signs of disease. It’s only in the overt stage that the hallmark symptoms arrive: dry eyes that burn, itch, or feel gritty, and a dry mouth that makes swallowing and speaking difficult. Most people are older than 40 when they finally reach diagnosis, often after years of vague or dismissed complaints.
Early Stage: Dryness and Fatigue
The first symptoms most people recognize are persistent dry eyes and dry mouth. Eyes may feel like they have sand in them. Your mouth may feel cottony, and you might notice you need water constantly to get through a meal. Dental cavities can increase sharply because saliva normally protects tooth enamel. Fatigue and joint pain are also extremely common early on, and they’re often the symptoms that affect quality of life most.
These “sicca” symptoms (the medical term for dryness) can remain the only problem for years. Many people with Sjögren’s never progress beyond this point. But the disease is still active underneath. Immune cells called lymphocytes slowly accumulate in clusters around the ducts of salivary and tear glands, gradually replacing functional tissue. Doctors can measure this damage with a lip biopsy, counting how many clusters of immune cells (called “foci”) appear in a small tissue sample. A focus score of 1 or higher per 4 square millimeters of gland tissue is one of the strongest diagnostic markers for Sjögren’s.
Moderate Stage: Extraglandular Involvement
Up to 50% of people with Sjögren’s eventually develop problems beyond the glands. This is sometimes called extraglandular or systemic involvement, and it marks a significant shift in the disease. The organs most commonly affected are the lungs, blood vessels, kidneys, skin, and thyroid.
About 20% of patients develop lung complications, most often interstitial lung disease, where inflammation gradually scars lung tissue and causes shortness of breath. Vasculitis, or inflammation of blood vessels, is another relatively common development. It can show up as purplish spots on the skin (palpable purpura) or tiny splinter-like hemorrhages under the fingernails. Kidney involvement, though less frequent, can affect the body’s ability to regulate acid levels in the blood.
Neurological complications deserve special attention because they’re often overlooked. Sjögren’s can affect both peripheral and central nervous systems. Peripheral nerve problems are more common and include small-fiber neuropathy (burning or tingling pain in the hands and feet), numbness, and autonomic dysfunction that can cause dizziness on standing or digestive issues. Less commonly, the central nervous system is involved, potentially causing cognitive difficulties sometimes called “brain fog,” seizures, or problems with vision and coordination. These neurological symptoms can occasionally appear before the classic dryness, making diagnosis especially challenging.
Lymphoma Risk: The Most Serious Concern
The complication that doctors monitor most closely is B-cell lymphoma, a type of blood cancer. People with Sjögren’s develop non-Hodgkin lymphoma at 15 to 20 times the rate of the general population, with roughly 5% to 10% of patients affected over their lifetime. The risk increases by about 2.2% for each year of age.
The transition doesn’t happen overnight. Certain warning signs raise suspicion: a parotid gland (the large salivary gland near the ear) that becomes permanently swollen, hard, or fixed on one side is the most common red flag. Other clinical predictors include swollen lymph nodes, an enlarged spleen, palpable purpura on the skin, and certain blood abnormalities like low complement C4 levels or the presence of cryoglobulins. A high focus score on biopsy (3 or above) is an independent risk factor for lymphoma, as is the presence of certain immune cell structures called germinal centers within the glands, which carry nearly an eightfold higher risk.
How Sjögren’s With Another Autoimmune Disease Differs
Sjögren’s can appear on its own (primary) or alongside another autoimmune condition like rheumatoid arthritis or lupus. When it develops alongside another disease, the timeline often looks different. Some people develop joint pain or other autoimmune symptoms years or even decades before any dryness appears. In one documented case, a young girl with juvenile arthritis didn’t develop Sjögren’s features until more than ten years after her arthritis began. In other cases, lung inflammation or neurological problems showed up years before dry eyes or mouth.
Despite these different entry points, glandular involvement (damage to the salivary and tear glands) almost always either precedes or closely coincides with problems in other organs. The disease ultimately converges on a similar path regardless of where it started.
How Progression Is Tracked
There’s no single blood test that tells you what “stage” you’re in, but doctors use a combination of tools to monitor the disease over time. The formal diagnostic criteria use a point-based scoring system: positive anti-SSA antibodies and a salivary gland biopsy with a focus score of 1 or higher each carry the most weight (3 points each). Three additional tests, measuring tear production, eye surface damage, and unstimulated saliva flow, each contribute 1 point. A combined score of 4 or higher confirms the diagnosis.
For ongoing monitoring, the EULAR Patient Reported Index tracks four key symptoms: mouth dryness, eye dryness, fatigue, and pain, all based on your own reporting. A more detailed tool called the ESSDAI evaluates 12 different organ systems but is used mostly in clinical trials. Regular bloodwork, including tests for extractable nuclear antibodies, immunoglobulin levels, and complement proteins, helps flag changes that could signal worsening disease or rising lymphoma risk. Because of the elevated cancer risk, surveillance for lymphoma is a standard part of long-term care, with doctors watching for the clinical red flags described above.
What Affects How Quickly It Progresses
Sjögren’s is highly variable. Some people live with mild dryness for decades. Others develop systemic complications within a few years. Several factors are associated with a more aggressive course: high focus scores on biopsy, the presence of germinal center structures in gland tissue, positive cryoglobulins, low complement levels, and parotid gland swelling. Younger age at diagnosis doesn’t necessarily mean worse outcomes, but it does mean a longer window during which complications can develop.
The disease overwhelmingly affects women, with female patients outnumbering males by roughly 14 to 1. Global prevalence of primary Sjögren’s is estimated at 0.01% to 0.05% of the population, making it relatively uncommon but far from rare. It remains one of the most underdiagnosed autoimmune conditions, with many patients waiting years between their first symptoms and a formal diagnosis.